95 related articles for article (PubMed ID: 23876214)
41. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
Amadori D; Milandri C; Comella G; Saracchini S; Salvagni S; Barone C; Bordonaro R; Gebbia V; Barbato A; Serra P; Gattuso D; Nanni O; Baconnet B; Gasparini G
Eur J Cancer; 2011 Sep; 47(14):2091-8. PubMed ID: 21665463
[TBL] [Abstract][Full Text] [Related]
42. Serpentine supravenous hyperpigmentation induced by docetaxel.
Das A; Kumar D; Mohanty S; Mondal AK; Chowdhury SN; Bandyopadhyay D
Indian J Dermatol Venereol Leprol; 2015; 81(4):434. PubMed ID: 25937137
[No Abstract] [Full Text] [Related]
43. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01.
Tinker AV; Gebski V; Fitzharris B; Buck M; Stuart-Harris R; Beale P; Goldrick A; Rischin D
Gynecol Oncol; 2007 Mar; 104(3):647-53. PubMed ID: 17079006
[TBL] [Abstract][Full Text] [Related]
44. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
Koutras AK; Kotoula V; Papadimitriou C; Dionysopoulos D; Zagouri F; Kalofonos HP; Kourea HP; Skarlos DV; Samantas E; Papadopoulou K; Kosmidis P; Pectasides D; Fountzilas G
Pharmacogenomics J; 2014 Jun; 14(3):248-55. PubMed ID: 24061601
[TBL] [Abstract][Full Text] [Related]
45. Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
Fukada J; Shigematsu N; Takeda A; Ohashi T; Tomita T; Shiotani A; Kunieda E; Kawaguchi O; Fujii M; Kubo A
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):417-24. PubMed ID: 19409727
[TBL] [Abstract][Full Text] [Related]
46. Single premedication dose of dexamethasone 20 mg IV before docetaxel administration.
Chouhan JD; Herrington JD
J Oncol Pharm Pract; 2011 Sep; 17(3):155-9. PubMed ID: 20447949
[TBL] [Abstract][Full Text] [Related]
47. Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study.
Seeholzer N; Thürlimann B; Köberle D; Hess D; Korte W
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):415-23. PubMed ID: 17581315
[TBL] [Abstract][Full Text] [Related]
48. Fatal hypersensitivity pneumonitis associated with docetaxel.
Gurram MK; Pulivarthi S; McGary CT
Tumori; 2013; 99(3):e100-3. PubMed ID: 24158075
[TBL] [Abstract][Full Text] [Related]
49. Hand-foot syndrome with docetaxel: a five-case series.
Farhat MH; El-Saghir NS; Shamseddine AI
Ann Saudi Med; 2008; 28(5):374-7. PubMed ID: 18779636
[No Abstract] [Full Text] [Related]
50. [Clinical utility of adjuvant TC regimen].
Aogi K
Nihon Rinsho; 2012 Sep; 70 Suppl 7():597-600. PubMed ID: 23350470
[No Abstract] [Full Text] [Related]
51. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
[TBL] [Abstract][Full Text] [Related]
52. [Poor outcome neutropenic enterocolitis after treatment with docetaxel in a breast cancer patient].
Cubo T; Padilla D; Villarejo P; López A; Delgado Y P Menéndez M
Rev Esp Enferm Dig; 2007 Aug; 99(8):480-2. PubMed ID: 18020871
[No Abstract] [Full Text] [Related]
53. Acute interstitial pneumopathy associated with docetaxel hypersensitivity.
Karacan O; Eyüboglu FO; Akçay S; Ozyilkan O
Onkologie; 2004 Dec; 27(6):563-5. PubMed ID: 15591716
[TBL] [Abstract][Full Text] [Related]
54. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
[TBL] [Abstract][Full Text] [Related]
55. Docetaxel administration schedule: from fever to tears? A review of randomised studies.
Engels FK; Verweij J
Eur J Cancer; 2005 May; 41(8):1117-26. PubMed ID: 15911234
[TBL] [Abstract][Full Text] [Related]
56. Cutaneous reaction associated with weekly docetaxel administration.
Chew L; Chuen VS
J Oncol Pharm Pract; 2009 Mar; 15(1):29-34. PubMed ID: 18753180
[TBL] [Abstract][Full Text] [Related]
57. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
Eckhoff L; Nielsen M; Moeller S; Knoop A
Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
[TBL] [Abstract][Full Text] [Related]
58. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
Aapro M; Tjulandin S; Bhar P; Gradishar W
Breast; 2011 Oct; 20(5):468-74. PubMed ID: 21843943
[TBL] [Abstract][Full Text] [Related]
59. [Pneumocystis pneumonia in two breast cancer patients treated with docetaxel: an unusual adverse event of chemotherapy].
Philippin-Lauridant G; Clatot F; Rigal O; Laberge-Le-Couteulx S; Guillemet C; Blot E
Rev Med Interne; 2010 Apr; 31(4):e1-3. PubMed ID: 19406536
[TBL] [Abstract][Full Text] [Related]
60. [Acute typhlitis associated with taxane-based chemotherapy].
Gagliano E; Tonante A; Taranto F; Mamo M; Sturniolo G; Colonese F; Sturniolo G
G Chir; 2010; 31(11-12):514-7. PubMed ID: 21232195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
